Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.

Abstract

Mantle-cell lymphoma (MCL) is characterized by poor prognosis with a median survival of only 3 to 4 years. To improve clinical outcome, the European MCL Network initiated a randomized trial comparing consolidation with myeloablative radiochemotherapy followed by autologous stem cell transplantation (ASCT) to alpha-interferon maintenance (IFN alpha) in first remission. Patients 65 years of age or younger with advanced-stage MCL were assigned to ASCT or IFN alpha after achievement of complete or partial remission by a cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-like induction therapy. According to the International Prognostic Index (IPI), 43% of patients had a low-risk, 41% a low-intermediate, 11% a high-intermediate, and 6% a high-risk profile. Sixty-two of 122 patients proceeded to ASCT and 60 received IFN alpha. Patients in the ASCT arm experienced a significantly longer progression-free survival (PFS) with a median of 39 months compared with 17 months for patients in the IFN alpha arm (P = .0108). The 3-year overall survival (OS) was 83% after ASCT versus 77% in the IFN group (P = .18). Early consolidation by myeloablative radiochemotherapy followed by ASCT is feasible and results in a significant prolongation of PFS in advanced-stage MCL. Longer follow-up is needed to determine the effect on OS.

• Authors: Martin Dreyling, Georg Lenz, Eva Hoster, Achiel Van Hoof, Christian Gisselbrecht, Rudolf Schmits, Bernd Metzner, Lorenz Truemper, Marcel Reiser, Hjalmar Steinhauer, Jean-Michel Boiron, Marc A Boogaerts, Ali Aldaoud, Vittorio Silingardi, Hanneke C Kluin-Nelemans, Joerg Hasford, Reza Parwaresch, Michael Unterhalt, Wolfgang Hiddemann
• Journal: Blood (Blood) Vol. 105 Issue 7 Pg. 2677-84 (Apr 01 2005) ISSN: 0006-4971 [Print] United States
• PMID: 15591112 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Vincristine
• Doxorubicin
• Cyclophosphamide
• Prednisone

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects)
• Combined Modality Therapy
• Cyclophosphamide (administration & dosage, adverse effects)
• Disease-Free Survival
• Doxorubicin (administration & dosage, adverse effects)
• Europe
• Female
• Hematopoietic Stem Cell Transplantation
• Humans
• Lymphoma, Mantle-Cell (drug therapy, mortality, radiotherapy)
• Male
• Middle Aged
• Prednisone (administration & dosage, adverse effects)
• Remission Induction
• Survival Analysis
• Transplantation, Autologous
• Vincristine (administration & dosage, adverse effects)
• Whole-Body Irradiation